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Abstract
Objective Dysregulation of the phosphatidylinositol-3-
kinase (PI3K) signaling pathway is a hallmark of human
cancer, occurring in a majority of tumors. Activation of this
pathway is critical for transformation and also for the
angiogenic switch, which is a key step for tumor progres-
sion. The objective of this study was to engineer a PI3K
inhibitor-loaded biodegradable nanoparticle and to evalu-
ate its efficacy.
Methods and results Here we report that a nanoparticle-
enabled targeting of the PI3K pathway results in inhibition
of downstream Akt phosphorylation, leading to inhibition
of proliferation and induction of apoptosis of B16/F10
melanoma. It, however, failed to exert a similar activity on
MDA-MB-231 breast cancer cells, resulting from reduced
internalization and processing of nanoparticles in this cell
line. Excitingly, the nanoparticle-enabled targeting of the
PI3K pathway resulted in inhibition of endothelial cell
proliferation and tubulogenesis, two key steps in tumor
angiogenesis. Furthermore, it inhibited both B16/F10- and
MDA-MB-231-induced angiogenesis in a zebrafish tumor
xenotransplant model.
Conclusion Our study, for the first time, shows that tar-
geting of the PI3K pathway using nanoparticles can offer
an attractive strategy for inhibiting tumor angiogenesis.
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One of the best characterized oncogenic signal transduction
cascades is the phosphatidylinositol-3-kinase (PI3K)-Akt
pathway, which is dysregulated in a majority of tumors [1].
PI3K is generally recruited downstream of activated
receptor tyrosine kinases, G-protein-coupled receptors or
integrins at the plasma membrane, where it catalyzes the
addition of a phosphate group at the 30-position of the
inositol ring of phosphoinositide/phosphatidylinositol (PI),
which binds to the pleckstrin-homology domain of multiple
proteins [2]. Activating mutations of the gene that encodes
the catalytic subunit of class 1A PI3K have been implicated
in ovarian and lung tumors [3, 4]. Similarly, phosphatase
PTEN, which deactivates PI3K, has been shown to be
mutationally or post translationally inactivated or inhibited
in other tumors, such as in glioblastoma, breast, melanoma,
lung, and hepatocellular carcinomas [5–9]. Furthermore,
PI3K signaling has been implicated in tumor angiogenesis
downstream of growth factors such as vascular endothelial
growth factor and hepatocyte growth factor [10, 11]. Thus,
inhibition of PI3K holds the promise of a multipronged
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strategy for tumor inhibition. However, clinical use of
PI3K inhibitors has faced hurdles arising from potential
systemic toxicities.
Nanotechnology holds great promise for the diagnosis
and treatment of cancer [12, 13]. Nanovector-based thera-
peutics have been preferentially delivered into tumors as
opposed to other tissue by exploiting the enhanced perme-
ability and retention (EPR) effect [12], a property that
permits nanoscale structures to be taken up passively into
tumors. Traditionally, nanovectors have been used to deli-
ver cytotoxic agents that are either difficult to formulate as a
result of hydrophobicity, such as in the case of paclitaxel
[14], or exhibit systemic toxicity, such as cardiotoxicity as
seen with doxorubicin [15]. Recently, we demonstrated that
a nanotechnology-based targeting of the mitogen-activated
protein kinase pathway predisposes the tumor to the effects
of cytotoxic chemotherapeutic agents, indicating that
combining signal transduction inhibitors with nanotech-
nology can emerge as a new paradigm for cancer therapy
[16]. In the current study, we engineered a biodegradable
polymeric nanoparticle as a vehicle for LY294002 to target
the PI3K oncogenic signaling pathway. LY294002 [2-(4-
morpholinyl)-8-phenylchromone] selectively inhibits PI3K
by competitively binding the ATP-binding pocket of PI3K’s
catalytic domain (IC50 = 1.40 lM) [17], and is hydropho-
bic, making it a suitable drug for formulation within a
nanoparticle. We demonstrate that a nanoparticle-mediated
delivery of a signal transduction inhibitor of PI3K can block
angiogenesis in vitro and in vivo.
Materials and methods
Materials
All the solvents were purchased from Sigma–Aldrich
(St. Louis, MO) and Fisher (Pittsburgh, PA), unless other-
wise stated and used without any further purification. The
poly (lactic-co-glycolic acid) (MW *66 kDa) having a
lactic/glycolic molar ratio of 50/50 was procured from
Lakeshore biomaterials (Brookwood Pharmaceutical Inc.,
AL). LY294002 was purchased from Tocris Bioscience
(Ellisville, MO). Epon-812 resin was purchased from Elec-
tron Microscopy Sciences (Hatfield, PA). Polyvinyl alcohol
(PVA) was purchased from Sigma–Aldrich. CellTiter 96
AQueous One Solution Cell Proliferation (MTS) Assay kit
was obtained from Promega Corporation (Madison, WI).
AnnexinV-Alexa Fluor 488, the LysoTracker Red probe
and the QTracker Red cell labeling kit were all from
Invitrogen (Carlsbad, CA). Monoclonal antibody specific
for actin was purchased from Sigma–Aldrich, whereas
polyclonal antibodies against the phosphorylated (p-AKT)
and total form (AKT) of AKT were from Cell Signaling
Technology (Danvers, MA). Vascular endothelial cell
growth factor (VEGF) was from R&D Systems (Minne-
apolis, MN). Matrigel basement membrane matrix was
obtained from BD Biosciences (San Jose, CA).
Synthesis of LY294002-encapsulated nanoparticle
(NP-LY)
Nanoparticles (NP) were formulated using an emulsion–
solvent evaporation technique. Briefly, 50 mg PLGA was
dissolved in 2.5 ml acetone and mixed with 3 mg of
LY294002 (dissolved in 0.5 ml methanol). The entire
solution was emulsified into 25 ml of 2% aqueous solution
of PVA (80% hydrolyzed, Mw *9,000–10,000) by slow
injection with constant homogenization using a tissue
homogenizer (Fisher Scientific Tissuemiser Homogenizer,
probe dimension: L x Dia. x Overall L = 8.3 9 0.7 9
28.6 cm). The emulsion was added to a 100 ml 0.2%
aqueous solution of PVA (80% hydrolyzed, Mw *9,000–
10,000) with rapid stirring for 4 h at room temperature to
evaporate any residual acetone and methanol. The desired
NP size fraction was recovered by ultracentrifugation at
20,000 and 80,0009 g and the NPs were lyophilized for
24 h. Sizing was performed by dynamic light scattering
(DLS) using a Malvern Nanozetasizer and transmission
electron microscopy (TEM) using a Philips system. To
quantify the LY294002 loading in the NPs, 5 mg of
lyophilized NP-LY was completely dissolved in 500 ll
DMF (the polymeric nanoparticles were completely dis-
solved in DMF, which ensures the complete release of all
LY29400 from the NP). The absorbance of LY294002 was
measured by UV–VIS spectra at 298 nm wavelength, at
which PLGA shows no absorbance. Furthermore, addition
of the same concentration of empty PLGA NP to a solution
of LY294002 in DMF showed that PLGA does not inter-
fere with UV–VIS spectra of LY294002. The loading was
quantified against a standard absorbance–concentration
linear plot, and expressed as the amount of LY294002 per
mg of NP-LY was quantified.
Transmission electron microscopy (TEM)
of the nanoparticles
The NP were fixed in 2.5% gluteraldehyde, 3% parafor-
maldehyde with 5% sucrose in 0.1 M sodium cacodylate
buffer (pH = 7.4), embedded in low temperature agarose
and post fixed in 1% OsO4 in veronal-acetate buffer. The
sample was stained in a block overnight with 0.5% uranyl
acetate in veronal-acetate buffer (pH = 6.0) then dehy-
drated and embedded in epon-812 resin. Sections were cut
on a Leica ultra cut UCT at a thickness of 70 nm using a
diamond knife, stained with 2.0% uranyl acetate followed
by 0.1% lead citrate and examined using a Philips EM410.
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Physicochemical release kinetics characterization
LY294002-encapsulated NP were suspended in 500 ll
of different cell lysates (MDA-MB-231, B16-F10, and
HUVEC in buffer) and sealed in a dialysis bag
(MWCO *1,000 Da). The dialysis bag was incubated in
1 ml of PBS buffer at room temperature with gentle
shaking. An aliquot (10 ll) was extracted from the incu-
bation medium at predetermined time intervals, dissolved
in 90 ll DMF, and released LY294002 was quantified by
UV–VIS spectroscopy at characteristic wavelength of
LY294002, k = 298 nm using absorbance–concentration
calibration curve. After withdrawing each aliquot, the
incubation medium was replenished by 10 ll of fresh PBS
to keep the outside volume constant.
Cell culture
Cancer cells were obtained from American Type Tissue
Culture Collection (Rockville, MD) and were maintained
in DMEM supplemented with 10% FBS and antibiotic/
antimycotic (all from Invitrogen). MDA-MB-231 human
breast adenocarcinoma, B16-F10 mouse melanoma and
Lewis lung carcinoma cells were grown on 100 mm dishes
and subcultured using trypsin (0.25%) and EDTA (0.01%).
Cells were switched to 1% serum overnight prior to drug
addition to synchronize the cells. All cells were seeded at
densities between 2,500 and 5,000 cells/cm2.
Human umbilical vein endothelial cells (HUVEC) were
obtained from Cambrex Bio Science (Hopkinton, MA) and
cultured in EGM-2 medium according to the manufac-
turer’s protocol. Cells were used between passages 2 and 5.
The cells were subcultured following trypsin (0.025%) and
EDTA (0.01%) application. For all experiments, HUVEC
were synchronized overnight using serum reduced medium
(0.1% FBS) prior to drug and growth factor addition,
except in the case of the tube assay. For the MTS assay and
immunoblotting, HUVEC were stimulated with 5 nM of
VEGF.
MTS cytotoxicity assay
Cancer or endothelial cells in 96-well plates (seeding
density between 2,500 and 5,000 per well) were incubated
with various doses of free LY294002 or NP-LY (equivalent
dose of free LY294002) for 24, 48, and 72 h. The per-
centage of viable cells were then quantified with 3-(4,5-
Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) from the CellTiter 96
AQueous One Solution kit. Briefly, the cells were washed
with PBS, incubated with 0.3 mg/ml of MTS, in basal
medium without phenol red for 4 h at 37C and absorbance
was then measured at 490 nm in a plate reader (Versamax,
Molecular Devices, Sunnyvale, CA). Final absorbance,
corresponding to cell viability, was plotted after subtracting
background values from each data point.
AnnexinV-FITC apoptosis study
Cells grown in 6-well plates were treated with drugs for
48 h, and incubated with 5 ll AnnexinV-Alexa Fluor
488 in binding buffer (10 mM HEPES, 140 mM NaCl,
2.5 mM CaCl2, pH 7.4) for 15 min in the dark,
according to the manufacturer’s protocol. Cells were then
washed with binding buffer, counterstained with propi-
dium iodide and immediately analyzed using a Becton
Dickinson FACSCalibur flow cytometer (excitation 488
and 585 nm, respectively). AnnexinV-Alexa Fluor 488,
propidium iodide or both were omitted for the negative
controls.
Nanoparticle internalization studies
Two experiments were performed in order to determine the
percentage of drug being internalized by the cells. In the
first such experiment, we used LysoTracker probes, which
accumulate in the acidic compartments of live cells and can
hence be used to track drug uptake. MDA-MB-231, B16-
F10 and HUVEC cells were seeded on glass coverslips in
24-well plates until subconfluency, and then treated with
5.6 mg/ml FITC-conjugated nanoparticles (FITC-NP) for a
time-course ranging from 30 min to 24 h. At the indicated
times, cells were washed twice in PBS and incubated in
LysoTracker Red (Ex: 577 nm; Em: 590 nm) for 30 min at
37C. Cells were then washed again, fixed in 4% parafor-
maldehyde and mounted using Prolong Gold antifade
reagent (Invitrogen). Images taken in three random fields
were captured at 20 and 409 using an inverted microscope
(Nikon Eclipse, Melville, NY) equipped with blue and
green filters in order to visualize FITC-NP and LysoTrac-
ker Red fluorescence, respectively. Cells incubated with
either only FITC-NP or Lysotracker Red served as negative
controls.
To synthesize FITC-PLGA conjugate, PLGA (50 mg)
was dissolved in 750 ll dichloromethane (DCM).
N- hydroxy succinimide (10 mg) and N-(3-Dimethylami-
nopropyl)-N-ethylcarbodiimide (15 mg) were added into
the reaction mixture and stirred at room temperature for
2 h. FITC (6 mg) was dissolved in a mixture of DCM
(25 ll) and pyridine (25 ll). FITC solution in pyridine was
added into the activated PLGA solution and the reaction
mixture was stirred at 4C for 24 h in dark. The reaction
was diluted with 50 ml DCM and quenched with 0.1 N
HCl solution. The organic layer was extracted with DCM
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(20 ml 9 2), washed with water (10 ml 9 2), brine
(20 ml) and dried over anhydrous sodium sulfate. The
organic layer was filtered and evaporated to obtain the
crude product. The PLGA-FITC conjugate was precipitated
out from the crude product by addition of diethyl ether
(40 ml). The polymer was centrifuged at 3,2209 g for
30 min. The supernatant was discarded and the polymer
was washed thoroughly by diethyl ether (5 ml 9 3) and
dried under vacuum overnight. The nanoparticles were
engineered from PLGA-FITC conjugate using the protocol
described earlier.
In the second experiment, HUVECs were incubated for
6 h (the time-point where maximal drug internalization
was observed from the previous assay) with 50 lM LY or
NP-LY, after which time, cells were washed with PBS and
collected in basic lysis buffer (pH 7.5) containing 50 mM
HEPES, 150 mM NaCl, 100 mM sodium fluoride, 1 mM
sodium orthovandate, 5 mM EDTA, 1 mM PMSF, 2 lg/ml
leupeptin, 5 lg/ml aprotinin and 0.5% Triton-X-100. The
lysed cells were lyophilized to remove water and then
suspended in 100 ll of DMF and shaken for 30 min to
dissolve all internalized LY294002 (free and encapsu-
lated). The undissolved lysed cells were centrifuged at
25,0009 g for 10 min. The supernatant was collected and
LY294002 was quantified by UV–VIS spectra at wave-
length k = 298 using a standard concentration–absorbance
curve. Untreated cells were processed similarly and were
used as blanks.
Immunoblotting
Cancer or endothelial cells were washed twice with PBS
and directly lysed in 39 loading buffer containing 12%
sodium dodecyl sulfate, 15% 2-mercaptoethanol, 1 mM
sodium orthovandate and protease inhibitor cocktail tablets
from Roche Applied Science (Indianapolis, IN). Cells were
further homogenized by passing the lysates three times
through an insulin needle. Samples were then heated for
5 min at 100C and equal amounts loaded onto tris-glycine
SDS–polyacrylamide gels. Proteins were electrophoreti-
cally transferred onto polyvinylidene difluoride mem-
branes, blocked for 1 h with 7% nonfat dry milk and
subsequently incubated overnight at 4C with primary
antibodies directed against the phosphorylated or total
forms of Akt. Proteins were detected with horseradish
peroxidase-conjugated antirabbit secondary antibodies
and Lumi-LightPLUS Western Blotting Substrate (Roche
Applied Science). The blots were developed using Gene-
Snap and optical densities of the protein bands quantified
using GeneTools (both from SynGene, Frederick, MD).
Predetermined molecular weight standards were used as
markers. Proteins were normalized against actin.
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Fig. 1 Synthesis and characterization of LY294002 encapsulated
nanoparticle: a Schematic representation of the synthesis of
LY294002 encapsulated nanoparticles by emulsion–evaporation
technique. b Size distribution (in nm) of the LY294002 encapsulated
nanoparticles by dynamic light scattering (DLS) experiment, and
c graph showing mean ± SEM size of the nanoparticles from n = 6
independent experiments. d Transmission electron microscopy (TEM)
image of LY294002 encapsulated nanoparticles. Bar represents
125 nm. e Graph shows the mean ± SEM loading of LY294002 in
the nanoparticle matrix (n = 7) as quantified using absorbance
against a standard absorbance curve. f Graph shows release kinetics
of LY294002 from the nanoparticle when incubated with different
cell lysates. The values on the Y-axis represent the % amount
of LY294002 released from the NP-LY (the % amount of
LY294002 = amount of LY released 9 100/total amount of LY
encapsulated in NP-LY)
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HUVEC tube assay
We quantified the effect of free LY294002 or NP-LY using
an in vitro angiogenic assay as follows. HUVEC were
seeded in 24-well plates at a density of 30,000 per well, on
glass coverslips that had been previously coated with
300 ll matrigel (diluted 1:2 in PBS) for 30 min at 37C, in
medium containing 50 lM of free LY294002 or nanopar-
ticle containing an equal amount of LY294002, and incu-
bated for 24 or 48 h. At each time point, cells were fixed
with 4% paraformaldehyde and immediately visualized
under inverted light microscopy at 209 magnification
(Nikon Eclipse). Ten fields of view per coverslip with five
coverslips per conditions were captured, and furthermore
three morphometric methods were used (NIS-elements
software, Nikon, Melville, NY) to quantify the results. In
the first such method, we measured the length of each tube
per field, in the second we measured the associated number
of nodes, whereas in the third method, we used a standard
graticule to measure the number of vessels falling on each
intersection.
Zebrafish xenograft assays
In order to assess the effect of NP-LY on in vivo angio-
genesis, we used the transparent Danio Rerio (zebrafish)
model. Zebrafish [TubingenAB] embryos were maintained
at 28C in standard E3 solution buffered with 2 mM
HEPES. Forty-eight hour postfertilization (hpf) embryos
were anesthetized with 0.04 mg/ml of Tricaine and were
dechorinated manually. Embryos were injected in the yolk
sac, near the subintestinal vessels, with around 500 cells
resuspended in matrigel, in the presence or absence of free
LY or NP-LY (equivalent to 200 lM of LY294002) and
with a constant volume of 9.2 nl using a Nanoject II
(Drummond Scientific), based on the protocol of Stefania
et al. [18]. The embryos were injected with either MDA-
MB-231/GFP or B16-F10 cells labeled with the QTracker
Red kit, according to the manufacturer’s protocol. Images
were taken both in real-time and after alkaline phosphatase
staining using nitroblue tetrazolium chloride and 5-bromo-
4-chloro-3-indolyl phosphate, toluidine salt (Roche, Nut-
ley, NJ), in order to visualize their vasculature. Brightfield
and fluorescence imaging of the embryos was performed
with a Nikon SMZ1500 stereomicroscope and SPOT Flex
camera. Image sequences were obtained with the same set-
up and exported as movies to match live flow patterns. The
embryos were monitored each day post injection (dpi) in
order to generate a cytotoxicity profile of the free drug
versus the NP. Morphometric analysis of subintestinal
vessels for each fish was done by measuring two inde-
pendent parameters using the NIS-elements software,
resulting in different profiles based on the type of
xenograft. All procedures were approved by Harvard
University IACUC.
For the zebrafish assays, MDA-MB-231 cells stably
expressing GFP (MDA-MB-231/GFP) were generated
using the pAcGFP-C1 expression plasmid (Clontech,
Mountain View, CA). This vector contains a codon-opti-
mized GFP gene, which yields maximal expression and
prolonged fluorescence in mammalian cells, as well as a
gene coding for neomycin resistance, thus allowing for
geneticin (G418) selection. 1.5 9 105 MDA-MB-231 cells
were seeded in 6-well plates overnight and then transfected
with 2 lg pAcGFP1-C1 using Lipofectin reagent (Invit-
rogen) for 24 h. Cells were allowed to recover for 24 h,
after which time, fresh growth medium supplemented with
1 mg/ml geneticin was added until drug-resistant colonies
appeared. These drug resistant cells were then propagated
and sorted based on the top 5% of fluorescence using a
MoFlo3 cell sorter.
Statistical analysis
All results were expressed as mean ± SEM of at least
triplicate samples. Statistical comparisons were obtained
using one-way analysis of variance followed by Newman
Keuls Post Hoc test. P \ 0.05 was considered significant.
Results and discussion
Nanotechnology has made tremendous progress in the
recent years and has evolved into a truly interdisciplinary
field bridging material science with medicine. The promise
of nanotechnology lies in the ability to engineer custom-
izable nanoscale constructs that can be loaded with one or
more payloads such as chemotherapeutics, targeting units,
imaging and diagnostic agents [19, 20]. In the current
study, we engineered LY294002-entrapped nanoparticles
(NP-LY) using an emulsion–solvent evaporation technique
(Fig. 1a), which resulted in generation of spherical nano-
particles as seen in the transmission electron micrograph
with a size range of 110.2 ± 5.9 nm in diameter as con-
firmed from DLS measurements (Fig. 1b, c, d). It is well
documented that nanoparticles in the optimal size range of
80–120 nm preferentially home into tumors by avoiding
the reticuloendothelial system [21]. The loading of the
encapsulated LY294002 was determined to be 2.98 ±
0.16 lg per mg of the LY-NP (n = 7 independent batches)
as determined by UV–VIS spectroscopy at the character-
istic wavelength of LY294002 (k = 298 nm) (Fig. 1e).
Drug release from nanoparticles and subsequent degrada-
tion is critical for biologic activity, and depends on
desorption of surface-bound drugs, diffusion through the
nanoparticle matrix, and erosion of the nanoparticle matrix
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[22]. We evaluated the release kinetics of LY294002 from
the NPs incubated with cell lysates, which mimics the in
vivo situation, wherein the tumor interstitial fluid is an
acidic and enzyme-enriched leachate formed from the
necrotic cells. Consistent with previous reports on nano-
particles with drug loaded in the matrix, there was a rapid
release of LY294002 within 7 h of incubation; it then
started to decay and became saturated after 10 h, with
sustained release for up to 72 h (Fig. 1f). Interestingly, the
rate and amount of LY294002 released from the nanopar-
ticles was dependent on the cell type, with maximal release
evident when incubated with HUVECs. The release
kinetics was similar when incubated with either MDA-MB-
231 or B16-F10 cells (Fig. 1f).
To measure cytotoxicity of NP-LY versus the free drug,
we incubated a panel of three cancer cell lines with free
LY294002 or nanoparticle containing an equivalent
amount of LY294002 for 24, 48, and 72 h, following which
we measured the metabolic activity of these cells using
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS). As shown in
Fig. 2a–c and supplementary Fig. 1, a slower onset of
cytotoxic effect was observed following NP-LY treatment
as compared with the free drug (LY294002), thus
confirming the temporal control over the release exerted by
encapsulating LY294002 in the nanoparticles. Interest-
ingly, we observed different levels of susceptibility to the
NP-LY treatment between the cancer cell lines. Significant
cytotoxic effect on MD-MB-231 breast adenocarcinoma
cells was apparent only at the higher concentrations and
following 72 h of incubation. In contrast, NP-LY signifi-
cantly inhibited the viability of LLC and B16-F10 cells.
For example, following 48 h of incubation with 50 lM of
LY294002 or NP-LY, the proportion of viable cells as
percentage of vehicle-treated control were 116% and 122%
for MDA-MB-231, 2 and 25% for LLC and 8 and 27% for
B16-F10, respectively, suggesting that MDA-MB-231 was
refractory while both B16-F10 and LLCs were sensitive to
the treatments with LY294002 or NP-LY. For further
studies we therefore selected B16/F10 and MDA-MB-231
cell lines as examples of susceptible and refractory cells,
respectively. Interestingly, while the mean level of acti-
vated Akt (downstream of PI3K) was higher in B16/F10
cells, the difference with the levels in the other cell lines
was statistically not significant (Fig. 2d), which indicated
that the refractoriness to nanoparticle-mediated targeting
could be independent of activation status of the target
protein.
Fig. 2 Concentration–effect of
NP-LY on viability of cancer
cells. a–c Graph shows the
viability of Breast
adenocarcinoma (MDA-MB-
231), Lewis lung carcinoma
(LLC) and melanoma (B16-
F10) cells treated with either
free drug (LY) or LY-
encapsulated nanoparticles
(NP-LY) for 48 h. The viability
of cells was quantified using the
MTS assay. Data represents
mean ± SEM from independent
triplicates. *P \ 0.05 compared
with vehicle-treated control
cells (ANOVA). d Basal level
of activation of PI3K signaling
in the three cell lines as
quantified by western blotting
for phosphorylated Akt. Data
expressed is mean ± SEM ratio
of phosphoAkt/total Akt from
n = 3 independent experiments.
The intensity of
chemiluminescent signal was
quantified using a Syngene
image analysis system
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To rationalize the differential sensitivity between both
cell lines to the treatments, we evaluated the mechanisms
of nanoparticle internalization using the LysoTracker Red
probe. We engineered nanoparticles from fluorescein-
labeled PLGA. B16-F10 or MDA-MB-231 cells were
treated with FITC-nanoparticles for defined time periods.
Lysosomal compartments of live cells were then stained
with LysoTracker Red probe and visualized using epi-
fluorescence microscopy such that the merged images
would appear yellow if the green FITC-nanoparticle were
internalized into the red-labeled lysosomes. As seen in
Fig. 3a, nanoparticles were taken up by the B16-F10 cells
earlier as compared with MDA-MB-231, with significant
internalization occurring as early as 15 min in B16-F10,
whereas comparable internalization was only observed at
later time points in MDA-MB-231 cells. Furthermore, the
colocalization of the FITC-nanoparticles and the Lyso-
Tracker Red signals indicated that the nanoparticles were
internalized into the lysosomes. This is a critical observa-
tion as this indicates that the acidic pH and the lysosomal
enzymes can facilitate the accelerated breakdown of the
PLGA, releasing the entrapped LY294002 from the matrix.
The limited/delayed internalization of the nanoparticle into
the lysosomes of the MDA-MB-231 cells could therefore
explain the refractoriness of the cell line to the treatment.
Alternatively, it could be correlated with the over-expres-
sion of ATP-binding cassette (ABC) transporters, which
have been implicated in conferring refractoriness to drugs
in this cell line by actively excreting the drug [23]. The
exact mechanism underlying the limited efficacy seen with
LY294002 in MDA-MB-231 remains to be investigated.
To further evaluate the underlying mechanisms of action
of LY294002-nanoparticles in cancer cells, MDA-MB-231
and B16-F10 were treated with 50 lM of LY294002 or
NP-LY and subjected to immunoblotting for quantifying
the levels of phospho- and total AKT. It is now well
established that the activation of PI3K results in the gen-
eration of PIP3 on the inner leaflet of the plasma mem-
brane, which recruits AKT by direct interaction with its PH
domain [24]. At the membrane a serine/threonine kinase,
PDK1, phosphorylates AKT on Thr308, which activates
AKT. A second phosphorylation at Ser473 increases the
Fig. 3 Mechanisms of nanoparticle uptake and downstream activity
in cancer cells. a Representative immunofluorescence images show
the localization of FITC-labeled nanoparticles. Breast adenocarci-
noma (MDA-MB-231) and melanoma cells (B16-F10) were seeded
on glass coverslips in 24-well plates and incubated with FITC-labeled
nanoparticles. At indicated time points, cells were stained with
LysoTracker Red to label the lysosomes, fixed and subjected to
fluorescence microscopy at 409 magnification. b A representative
blot from independent triplicates show the effect of NP-LY and free
LY294002 treatments on the levels of phospho-Akt in B16/F10 and
MDA-MB-231 cells
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activity. Indeed, AKT was found to be phosphorylated in
both MDA-MB-231 and B16/F10 melanoma cells. Inter-
estingly, whereas treatment with LY294002 or NP-LY had
only minimal effect on inhibiting the phosphorylation of
AKT in MDA-MB-231 cells, both free LY294002 and
NP-LY inhibited AKT signaling in B16-F10 cells by up to
7-fold (Fig. 3b). Together with the uptake studies, this
differential inhibition of AKT signaling could potentially
explain the distinct sensitivities of MDA-MB-231 and B16-
F10 with respect to both free and encapsulated LY294002.
One of the key biologic consequences of activated AKT
signaling is the inhibition of apoptosis through phosphor-
ylation of several components of the cell death machinery.
For example, AKT-mediated phosphorylation of BAD, a
pro-apoptotic member of the BLC2 family of proteins,
prevents its nonfunctional hereterodimerization with the
survival factor BCL-XL, leading to restoration of the
antiapoptotic function of BCL-XL [25]. Furthermore, AKT-
induced phosphorylation can inhibit the catalytic activity of
pro-apoptotic caspase-9 [26] and also prevent the nuclear
translocation of FKHR, a member of the Forkhead family
of transcription factors, resulting in inactivation of FKHR
gene targets including pro-apoptotic proteins such as BIM
and FAS ligands [27]. To determine whether the
LY294002 and NP-LY-induced inhibition of PI3K and
subsequent block of AKT activation results in apoptosis of
tumor cells, we labeled the cells with AnnexinV (conju-
gated to FITC), which binds to phosphatidylserine
expressed on cell surface during apoptosis. Simultaneous
staining of the cells with the vital dye, propidium iodide
(PI), allowed us to get a profile of early (AnnexinV-
FITC ?ve, PI-ve) versus late (AnnexinV-FITC ?ve;
-
23
1
Control                                                       LY294002                                     NP-LY294002
10
M
D
B
16
-F
1
A
Fig. 4 Treatment with LY294002 or NP-LY induces apoptosis. The
percentages of early and late apoptosis stages were quantified using
the Annexin V-FITC/propidium iodide FACS assay. Cells were
treated with LY or NP-LY for 48 h and then subjected to FACS
analysis. Cells were gated into four quadrants based on red (FL2-H)
versus green (FL1-H) fluorescence. The percentage of cells in each
quadrant is shown in the tables below and is expressed as
mean ± SEM. Images shown are representatives from independent
triplicates
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PI ?ve) apoptosis (Fig. 4). Fluorescence activated cell
sorting analysis following annexinV-FITC and PI staining
revealed that only 3.11 and 0.09% of the MDA-MB-231
cells were in early and late apoptosis following LY294002
treatment. Similarly, treatment with NP-LY resulted in
0.57 and 0.05% of the MDA-MB-231 cells in early and late
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Fig. 5 Effect of NP-LY on angiogenesis in vitro. a Immunofluores-
cence images show the temporal uptake of FITC-labeled nanoparti-
cles in HUVECs, which were counterstained with LysoTracker Red.
b Representative western blot showing phospho and total Akt levels
in HUVEC treated with LY294002 or NP-LY for 24 h, followed by
15 min of VEGF. The graph shows densitometric analysis of intensity
levels of the chemiluminescent signal from n = 2 independent
experiments. c Graph shows the effect of different treatments on
VEGF-induced proliferation of HUVECs. The viability of the cells
was quantified using the MTS assay. Data shows mean ± SEM
(n = 3). # P, *** P \ 0.001 vs vehicle-treated controls. ? P \ 0.05
vs VEGF-treated group. d Graph shows the intracellular levels of
LY294002 when the HUVECs were incubated with free LY294002 or
nanoparticles loaded with an equivalent concentration of LY294002.
Data represents mean ± SEM from at least independent triplicates.
e Representative micrographs show the effects of LY294002 and
NP-LY on HUVEC tube formation were quantified by seeding cells
on matrigel in the presence or absence of the drugs for 24 and 48 h.
Graphs show the quantification of the images using three morpho-
metric analyses. Data shows mean ± SEM. # P \ 0.05 vs vehicle-
treated controls
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apoptosis phases, respectively. In contrast, treatment of
B16/F10 melanoma cells with LY294002 resulted in 61.64
and 0.22% of the cells shifting to early and late apoptosis,
respectively. Similarly, treatment with NP-LY resulted in
35.04 and 0.47% of the cells shifting to early and late
apoptosis, consistent with the temporal nature release of
LY294002 from the nanoparticles. Intriguingly, the failure
of LY294002 or NP-LY to induce apoptosis in the MDA-
MB-231 cell line despite the basal activated state of AKT
in this cell line is not entirely unexpected. While it may
arise from reduced uptake or increased efflux of the
nanoparticle inside the cells, as observed in this study, it
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Fig. 6 Effects of NP-LY on
B16-F10-mediated angiogenesis
in vivo using a zebrafish
xenograft assay. Zebrafish were
xenografted with matrigel-
encapsulated B16-F10
melanoma cells labeled with
QTracker Red. The cells were
injected into the yolk in close
proximity to the subintestinal
vessels. Zebrafish embryos were
injected with FITC-nanoparticle
and visualized 2 days post
injection (2 dpi) under a bright
field and b fluorescence
microscopy, respectively.
Treatment with vehicle had no
effect on angiogenesis induced
by the tumor cells (c), while
injecting NP-LY completely
abrogated the angiogenic
response (d). The vasculature
was stained (blue) using
alkaline phosphatase staining
and the subintestinal vessels
(black arrows) were imaged
under bright field microscopy.
Fish were also imaged under
fluorescence in order to
visualize the cancer cells, which
were localized next to the
subintestinal vessels (c inset,
white arrow). e Graph shows
morphometric quantification of
the effect of treatment on
xenograft-induced angiogenesis.
Data shown are mean ± SEM
(n = 16). # P \ 0.05 compared
with WT embryos.
*** P \ 0.01 compared with
B16-F10/Red xenografts
334 Angiogenesis (2009) 12:325–338
123
may also arise from compensatory mechanisms that are
simultaneously activated in cancer cells [28, 29]. For
example, in an elegant study, Rosen et al. demonstrated
that induction of PTEN (thereby downregulation of PI3K
signaling) and inhibition of epidermal growth factor
receptor induced a synergistic apoptosis response [30] by
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Fig. 7 Effects of NP-LY on
MDA-MB-231/GFP-mediated
angiogenesis in vivo using the
zebrafish xenograft assay.
Zebrafishes were transplanted
with matrigel-encapsulated
GFP-labeled MDA-MB-231
cells, in the absence (c, d) or
presence (e, f) of NP-LY for
2 days, as in Fig. 6. Wild type
(uninjected) fish served as
internal controls (a, b).
Representative bright field and
fluorescent images taken in real-
time are shown in the left
panels, whereas alkaline
phosphatase vessel staining is
shown on the right panels.
g Graph represents
morphometric quantification of
the effect of treatment on
xenograft-induced angiogenesis.
Data shown are mean SEM
(n = 3–10). Black
arrows = subintestinal vessels;
white arrows = MDA-MB-231/
GFP. # P \ 0.05 compared with
WT embryos. * P \ 0.05
compared with MDA-MB-231/
GFP xenografts (ANOVA
followed by Newman Keuls
Post test)
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blocking distinct pathways that independently converge
into phosphorylation of the pro-apoptotic protein BAD at
two distinct sites. Indeed, in another study, a combination
of an AKT/mammalian target of rapamycin (mTOR)
inhibitor and a MAPK kinase 1 inhibitor were shown to
dramatically impact tumor progression in a hormone-
refractory prostate cancer model [31], indicating that tumor
progression can depend on multiple independent signaling
pathways, and any broad nanoparticle-based strategy for
targeting tumor cells will potentially require the inhibition
of multiple targets besides PI3K.
A key event during tumor progression is the requirement
for angiogenesis, or the formation of new blood vessels
from an existing vascular bed in order for the tumor to grow
beyond 1 mm3 in volume [32]. This ‘angiogenic switch’ has
been implicated as a critical step for tumor progression and
metastasis [33]. Interestingly, a critical promoter for tumor
angiogenesis is the activation of the PI3K/AKT pathway.
We rationalized that the discrepancy in the susceptibility of
different tumors to PI3K inhibitors could potentially be
overcome by nanoparticle-mediated targeting of the
activated PI3K/AKT signaling cascade in endothelial cells,
given that the angiogenic process is consistent across dif-
ferent tumors. Indeed as shown in Fig. 5a, we observed a
rapid uptake of the FITC-labeled NP-LY into human
umbilical vein endothelial cells (HUVECs) within 30 min
of incubation, with internalization into the lysosomes
clearly evident by 6 h, as seen from the colocalization of the
signals from the FITC-nanoparticle and the LysoTracker
Red-labeled lysosomes. Interestingly the FITC signal and
the LysoTracker signal disengaged by 12 h, suggesting that
the nanoparticles are processed in the lysosomes and the
active agents are released into the cytosol. Furthermore, the
intracellular level of LY294002 following incubation of
the cells with LY-NP or LY294002 was found to be similar
(Fig. 5d). Indeed, western blot analysis of the activated Akt
revealed that 24 h incubation with both LY294002 and NP-
LY at 50 lM concentration resulted in complete inhibition
of VEGF-induced activated PI3K-mediated phosphoryla-
tion of Akt in the HUVEC cells (Fig. 5b).
The angiogenesis process involves a temporal series of
discrete but overlapping steps, including proliferation and
Fig. 8 Dose–effect of free
LY294002 or NP-LY on B16-
F10-mediated angiogenesis in
vivo. Zebrafishes were
transplanted with B16/F10 cells
along with free drug or NP-LY
(50, 100 and 200 lM). After
2 dpi, the vasculature was
stained for alkaline phosphatase
expression. Representative
bright field images show effect
of different concentrations of
free LY294002, or an equivalent
concentration of LY294002 in
the nanoparticle on xenograft-
induced angiogenesis from the
SIV. Graph shows
morphometric quantification
(mean ± SEM number nodes in
SIV n = 13–15). # P \ 0.05
compared with B16-F10/Red
xenografts
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tubulogenesis of endothelial cells [34]. We decided to
evaluate the activity of the NP-LY on endothelial cell
proliferation. Serum-starved synchronized HUVECs were
stimulated with vascular endothelial growth factor (VEGF)
in the presence of increasing concentrations of LY294002
or NP-LY. Cell proliferation at the end of 48 h was
quantified using an MTS assay. As shown in Fig. 5c,
treatment with LY294002 or LY-nanoparticle blocked
VEGF-induced cell proliferation, consistent with the inhi-
bition of PI3K signaling.
During angiogenesis, proliferation of endothelial cells is
followed by tubulogenesis, which is mimicked when
endothelial cells are plated on growth factor-enriched
matrigel, a tumor extracellular matrix. As shown in Fig. 5e,
HUVECs formed a well-developed vascular network of
tubes on matrigel in the vehicle-treated group, which was
inhibited by LY294002 and NP-LY (Fig. 5e). Interestingly,
while both free LY294002 and NP-LY significantly
inhibited tube formation within 24 h, the free drug was
more potent, confirming the temporal nature of release of
active drug from the nanoparticle. These results indicated
that PI3K plays a key role in critical steps of angiogenesis,
and therefore could emerge as an exciting target for the
inhibition of tumor angiogenesis, consistent with earlier
observations [35].
To test whether the NP-LY can inhibit angiogenesis in
vivo, we harnessed a zebrafish tumor xenograft model,
which has evolved as a powerful model for studying angi-
ogenesis [36]. As shown in Fig. 6a, b, the injected nano-
particles (FITC-labeled) were restricted in close proximity
to the subintestinal vessels, and by themselves, did not
induce cytotoxicity. Similarly, the Qtracker-labeled B16/
F10 cells were found to be viable and growing in the yolk,
in close proximity to SIV space (Fig. 6c inset), and in some
cases exhibited metastasis (results are not shown). The
tumor cells were found to induce angiogenesis as clearly
seen from the remodeling or budding of vascular structures
from the subintestinal vessels, consistent with previous
observations [37]. The presence of NP-LY completely
inhibited angiogenesis from the subintestinal vessel
(Fig. 6d). Similarly, in fish injected with MDA-MB-231/
GFP cells, morphometric analysis revealed that the xeno-
graft-induced angiogenesis was significantly greater than
the angiogenesis observed in vehicle-controls (Fig. 7a–d).
Interestingly, the injection of NP-LY abrogated this vessel
development (Fig. 7e–f). Additionally, in a dose-efficacy
study, we observed a marked variability with the free
LY294002 as compared with the robust antiangiogenic
response elicited by NP-LY, which could arise from the
sustained local delivery of LY294002 from the nanoparti-
cles (Fig. 8). Our results suggest that nanoparticle-mediated
delivery of PI3K inhibitors for targeting tumor angiogenesis
could be an attractive approach, even if there are differences
in the susceptibility of tumor cells to nanoparticle-mediated
inhibition of PI3K. While the zebrafish assay is not opti-
mized for doing homing studies, the preferential passive
homing to angiogenic vessels by nanoparticle is well doc-
umented [38, 39] and, to the best of our knowledge, has not
been shown to be taken up by endothelial cells lining nor-
mal vessels. However, it is likely that nanoparticles can be
internalized by endothelial cells lining angiogenic tumor
vasculature, which exhibit abnormal flow dynamics or sta-
sis. Targeting the tumor vasculature can further be opti-
mized by decorating the nanoparticle surface with ‘homing’
peptides against epitopes specifically expressed on tumor
vasculature, such as avb3 integrins [40]. Indeed an optimal
strategy for effective anticancer outcome could combine
such a signal-transduction inhibition-based antiangiogene-
sis approach with a cytotoxic chemotherapeutic agent for
optimal anticancer outcome, which we are currently
exploring in our laboratory.
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